GSK acquires Reliant in move to boost cardio franchise

Share this article:

In a move to bolster its cardiovascular product line, GlaxoSmithKline has announced plans to purchase New Jersey-based Reliant Pharmaceuticals for $1.65 billion in cash.

The acquisition will strengthen GSK's cardiovascular drugs area anchored by its hypertension and congestive heart failure treatment Coreg, which sold $1.1 billion in the first nine months of 2007.

The acquisition adds Reliant's triglyceride-lowerer Lovaza which had sales of $206 million in the first nine months of 2007. Reliant's other drugs include Dyna Circ and InnoPran XL to treat high blood pressure and Rythmol SR for abnormal heartbeats.

Privately held Reliant reported sales growth of 62% in the first nine months of 2007, to $341 million. The company has 1,000 employees, 800 of them in sales, a GSK spokesman said in a published report.

Reliant's CEO Bradley Sheares said in a statement that his sales force has “demonstrated their worth in building a formidable Lovaza franchise in less than 24 months.”

The acquisition is subject to approval by the US Federal Trade Commission and is expected to conclude before year-end.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.